Human 3D In Vitro Models for Developmental Neurotoxicity

Lade...
Vorschaubild
Dateien
Zu diesem Dokument gibt es keine Dateien.
Datum
2018
Autor:innen
Smirnova, Lena
Herausgeber:innen
Kontakt
ISSN der Zeitschrift
Electronic ISSN
ISBN
Bibliografische Daten
Verlag
Schriftenreihe
Auflagebezeichnung
URI (zitierfähiger Link)
ArXiv-ID
Internationale Patentnummer
Angaben zur Forschungsförderung
Projekt
Open Access-Veröffentlichung
Sammlungen
Core Facility der Universität Konstanz
Gesperrt bis
Titel in einer weiteren Sprache
Forschungsvorhaben
Organisationseinheiten
Zeitschriftenheft
Publikationstyp
Beitrag zu einem Sammelband
Publikationsstatus
Published
Erschienen in
SLIKKER, William, ed. and others. Handbook of Developmental Neurotoxicology. Second edition. London: Academic, 2018, pp. 163-172. ISBN 978-0-12-809405-1. Available under: doi: 10.1016/B978-0-12-809405-1.00014-6
Zusammenfassung

Developmental neurotoxicity (DNT) testing of industrial chemicals is an increasingly perceived societal need in light of strong increases in neurodevelopmental disorders including autism. The current testing approach for DNT in vivo does not satisfy these needs because despite enormous costs and animal use, there appears to be limited predictivity for its health effects in humans. The Center for Alternatives to Animal Testing (CAAT) in the United States and Europe along with its partners has steered a process of developing in vitro strategies for DNT, which is summarized here. This process has prioritized models, cellular key events, reference compounds, and others. This shaped a 3DNT approach, which aims to employ three-dimensional (3D) microphysiological models such as an induced pluripotent stem cells–derived mini-brain model from our laboratory. These complex models have to be complemented with, favorably 3D, models of homogenous cell models for pathway identification; an example of a 3D dopaminergic neurons (LUHMES) model is given. The human mini-brain model offers opportunities beyond studying developmental effects. It is also undergoing further amendments such as the addition of microglia and a blood–brain barrier. A major recent breakthrough showed that the model could be frozen for stockpiling and transport. This enables us to make the model readily available via commercial vendors. For this purpose, a Johns Hopkins spin-off biotech company, Organome LLC, was formed.

Zusammenfassung in einer weiteren Sprache
Fachgebiet (DDC)
570 Biowissenschaften, Biologie
Schlagwörter
neurodevelopment; brain; cell culture; organoids; spheroids; microphysiological systems; mini-brain
Konferenz
Rezension
undefined / . - undefined, undefined
Zitieren
ISO 690SMIRNOVA, Lena, Thomas HARTUNG, 2018. Human 3D In Vitro Models for Developmental Neurotoxicity. In: SLIKKER, William, ed. and others. Handbook of Developmental Neurotoxicology. Second edition. London: Academic, 2018, pp. 163-172. ISBN 978-0-12-809405-1. Available under: doi: 10.1016/B978-0-12-809405-1.00014-6
BibTex
@incollection{Smirnova2018Human-41991,
  year={2018},
  doi={10.1016/B978-0-12-809405-1.00014-6},
  title={Human 3D In Vitro Models for Developmental Neurotoxicity},
  edition={Second edition},
  isbn={978-0-12-809405-1},
  publisher={Academic},
  address={London},
  booktitle={Handbook of Developmental Neurotoxicology},
  pages={163--172},
  editor={Slikker, William},
  author={Smirnova, Lena and Hartung, Thomas}
}
RDF
<rdf:RDF
    xmlns:dcterms="http://purl.org/dc/terms/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
    xmlns:bibo="http://purl.org/ontology/bibo/"
    xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#"
    xmlns:foaf="http://xmlns.com/foaf/0.1/"
    xmlns:void="http://rdfs.org/ns/void#"
    xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > 
  <rdf:Description rdf:about="https://kops.uni-konstanz.de/server/rdf/resource/123456789/41991">
    <bibo:uri rdf:resource="https://kops.uni-konstanz.de/handle/123456789/41991"/>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2018-04-10T08:44:17Z</dc:date>
    <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <dc:contributor>Hartung, Thomas</dc:contributor>
    <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <foaf:homepage rdf:resource="http://localhost:8080/"/>
    <dc:creator>Hartung, Thomas</dc:creator>
    <dc:creator>Smirnova, Lena</dc:creator>
    <dc:language>eng</dc:language>
    <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2018-04-10T08:44:17Z</dcterms:available>
    <dc:contributor>Smirnova, Lena</dc:contributor>
    <dcterms:issued>2018</dcterms:issued>
    <dcterms:abstract xml:lang="eng">Developmental neurotoxicity (DNT) testing of industrial chemicals is an increasingly perceived societal need in light of strong increases in neurodevelopmental disorders including autism. The current testing approach for DNT in vivo does not satisfy these needs because despite enormous costs and animal use, there appears to be limited predictivity for its health effects in humans. The Center for Alternatives to Animal Testing (CAAT) in the United States and Europe along with its partners has steered a process of developing in vitro strategies for DNT, which is summarized here. This process has prioritized models, cellular key events, reference compounds, and others. This shaped a 3DNT approach, which aims to employ three-dimensional (3D) microphysiological models such as an induced pluripotent stem cells–derived mini-brain model from our laboratory. These complex models have to be complemented with, favorably 3D, models of homogenous cell models for pathway identification; an example of a 3D dopaminergic neurons (LUHMES) model is given. The human mini-brain model offers opportunities beyond studying developmental effects. It is also undergoing further amendments such as the addition of microglia and a blood–brain barrier. A major recent breakthrough showed that the model could be frozen for stockpiling and transport. This enables us to make the model readily available via commercial vendors. For this purpose, a Johns Hopkins spin-off biotech company, Organome LLC, was formed.</dcterms:abstract>
    <dcterms:title>Human 3D In Vitro Models for Developmental Neurotoxicity</dcterms:title>
    <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/>
  </rdf:Description>
</rdf:RDF>
Interner Vermerk
xmlui.Submission.submit.DescribeStep.inputForms.label.kops_note_fromSubmitter
Kontakt
URL der Originalveröffentl.
Prüfdatum der URL
Prüfungsdatum der Dissertation
Finanzierungsart
Kommentar zur Publikation
Allianzlizenz
Corresponding Authors der Uni Konstanz vorhanden
Internationale Co-Autor:innen
Universitätsbibliographie
Ja
Begutachtet
Diese Publikation teilen